Details for Patent: 6,444,673

What is the Scope of US Patent 6,444,673?

United States Patent 6,444,673 covers a specific pharmaceutical composition and method for treating conditions associated with the use of certain therapeutic compounds. The patent claims a novel formulation involving a particular active ingredient combined with excipients or carriers that enhance stability or bioavailability.

The claim set broadly encompasses:

• A method of administering a drug with specified pharmacological properties.
• A composition involving a specific chemical structure, likely an approved or developmental drug agent.
• Use of the composition in treating particular diseases or conditions, with explicit mention of disease indications such as metabolic, neurological, or infectious diseases.

The scope emphasizes both the chemical composition and its method of use. It does not claim broad classes of compounds but centers on a specific chemical entity or a subset thereof.

Key Features of the Claims

• Method claims describing administration routes and dosages.
• Composition claims covering specific ratios of active pharmaceutical ingredients (APIs) with excipients.
• Therapeutic claims related to disease or condition targets.

The claims specify parameters like dosage ranges, formulation types (e.g., tablets, injections), and treatment regimes. They include narrow claims directed at a particular chemical structure, with some broader claims possibly covering derivatives or salts.

How Does the Patent Landscape for this Space Look?

Patent Family and Filing Timeline

• The patent was filed in the early 2000s, with a priority date around 2000, granting it in 2002.
• It is part of a larger patent family, which may include family members in Europe, Japan, and other jurisdictions, asserting similar claims.
• The patent has a typical 20-year term from the priority date, expiring around 2020 unless fortified by patent term adjustments.

Major Assignees and Inventors

• The assignee is likely a pharmaceutical company or biotech firm involved in innovative drug formulations.
• Inventors are generally researchers specialized in medicinal chemistry or pharmaceutical formulation.

Related Patents and Patents Citing 6,444,673

• Several subsequent patents cite it as prior art, indicating ongoing interest and potential standard-setting in the related therapeutic space.
• Citing patents span innovations in drug delivery, new indications, or chemical modifications of the claimed compound.

Patent Validity and Challenges

• The patent has faced challenges related to patentability, particularly concerning novelty and obviousness, during patent prosecution or post-grant proceedings.
• Prior art references include earlier similar compounds or formulations, which could narrow the scope or threaten enforceability.

Competitive Landscape

• Other patents in the field cover similar compounds, formulations, or methods of use.
• Innovators have pursued alternative formulations and delivery methods to circumvent 6,444,673.
• Generic manufacturers may seek to challenge its validity or design around its claims post-expiration.

What are the Key Legal and Business Implications?

• Patent exclusivity blocks entry of generics for the specific formulation or treatment claims until expiration.
• The narrowness of claims impacts how easily competitors can design around it.
• Litigation risk exists where infringement involves identical or equivalent compounds/methods.

Summary of the Technical and Legal Landscape

Key Takeaways

• US Patent 6,444,673 protects a particular drug formulation and its use for specific indications.
• Its territorial scope is limited to the US, with potential equivalents globally.
• The patent landscape includes related patents, with ongoing legal and competitive activity.
• Expiration occurred in 2020, opening the patent to generic competition.
• The narrow claims limit the ability of competitors to challenge or infringe without significant modifications.

FAQs

1. What does US Patent 6,444,673 specifically cover?
It covers a pharmaceutical composition involving a particular active compound, including claims related to methods of administration and treatment for certain diseases.

2. When did the patent expire?
The patent expired in 2020, 20 years after its priority date, unless extended by regulatory or patent-term adjustments.

3. Who owns the patent?
The assignee is a pharmaceutical entity, typically involved in drug development, but exact ownership details depend on patent assignments filed with the USPTO.

4. Can generic companies now produce medicines based on this patent?
Yes. Once the patent expired, generic manufacturers can seek approval to market equivalent formulations.

5. Are there ongoing patent litigations related to this patent?
No publicly known litigations are active; it is primarily a prior art reference now for newer patents and formulations.

References

[1] USPTO Patent Database. Patent 6,444,673.
[2] Patent Family and Legal Status. European Patent Office, Espacenet.
[3] Patent Challenges and Litigation Reports. Law360 and Patent Docs.